‘Dangling’ Accelerated Approval Reviews Expand At US FDA

 
• By Michael McCaughan

The oncologic drugs advisory committee’s upcoming reviews are moving beyond the PD-1/PDL-1 inhibitor class – and to a very different type of sponsor.

US FDA's oncology center is starting to look at a wider array of accelerated approvals as it continues to consider 'dangling' indications. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers